Skip Ribbon Commands
Skip to main content
Sign In

25546 BCR/ABL1, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies (BA190)

BCR/ABL1, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies (BA190)
Test Code: BC190SO
Synonyms/Keywords
Philadelphia chromosome, Ph bone marrow/blood
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
B lymphoblastic leukemia (B-ALL)
BCR ABL
BCR/ABL
BCR-ABL1
T lymphoblastic leukemia (T-ALL)
t(9;22)
Useful For
Monitoring response to therapy in patients with known e1/a2 BCR/ABL1 (p190) fusion forms.
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
 Submit 1 of the following specimens:​ ​ ​ ​ ​ ​ ​
​No ​Whole Blood ​EDTA Lavender Top Tube (LTT) ​ACD Yellow Top Tube (YTT) ​10 mL 4 mL
No ​Bone Marrow ​EDTA Lavender Top Tube (LTT) ​ACD Yellow Top Tube (YTT) ​4 mL 2 mL
Collection Processing Instructions

Refrigerate specimens must arrive within 5 days (120 hours) of collection, and ambient specimens must arrive within 3 days (72 hours) of collection. Collect and package specimen as close to shipping time as possible.

Necessary Information:

The following information is required:

1. Pertinent clinical history including if the patient has a diagnosis of chronic myelogenous leukemia or other BCR/ABL1-positive neoplasm

2. Date of collection

3. Specimen source (blood or bone marrow)

Specimen Stability Information
Specimen Type Temperature Time
​Varies ​ ​Refrigerated (preferred) 5 days
​Ambient ​72 hours
Rejection Criteria
Gross hemolysis or moderately to severely clotted
Performing Laboratory Information
Performing Location Day(s) Test Performed Report Available Methodology/Instrumentation
​Mayo Clinic Laboratories ​Monday through Saturday ​4 to 8 days ​Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Reference Lab
Test Information

mRNA transcribed from BCR/ABL (fusion of the breakpoint cluster region gene [BCR]at chromosome 22q11 to the Abelson gene [ABL] at chromosome 9q23) is detected in all chronic myelogenous leukemia (CML) patients and a subset of both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. Although breakpoints in the BCR and ABL genes may occur in a variety of locations, splicing of the primary RNA transcripts result in only 8 fusion site variants (e1/a2, e6/a2, e13/a2, e14/a2, e19/a2, and e1/a3, e13/a3, e14/a3), which incorporate the entire sequence of the exons on both sides of the fusion site. The e1/a2 and e1/a3 fusion forms produce a 190-kDa protein designated p190. This bcr/abl protein form is found in approximately 75% of childhood ALL patients and approximately 50% of adult ALL patients, with the majority arising from e1/a2 mRNA. The p190 is also the predominant fusion form in a small subset of CML patients, although the vast majority of CML cases contain the p210 protein, typically from e13/a2 or e14/a2 mRNA fusions. Other fusion forms are very rare.

Quantitative reverse-transcription PCR (qRT-PCR) is the most sensitive method for monitoring bcr/abl levels during treatment. This test detects mRNA coding for the most common p190 fusion form (e1/a2).

Reference Range Information
Performing Location Reference Range
​Mayo Clinic Laboratories ​ ​ ​The presence or absence of the BCR/ABL1 mRNA fusion form producing the p190 fusion protein is reported. If positive, the level is reported as the ratio of BCR/ABL1 (p190) transcript to ABL1 transcript in the form of a percentage.
Interpretation
An interpretive report will be provided.
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​81207
Synonyms/Keywords
Philadelphia chromosome, Ph bone marrow/blood
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
B lymphoblastic leukemia (B-ALL)
BCR ABL
BCR/ABL
BCR-ABL1
T lymphoblastic leukemia (T-ALL)
t(9;22)
Ordering Applications
Ordering Application Description
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
 Submit 1 of the following specimens:​ ​ ​ ​ ​ ​ ​
​No ​Whole Blood ​EDTA Lavender Top Tube (LTT) ​ACD Yellow Top Tube (YTT) ​10 mL 4 mL
No ​Bone Marrow ​EDTA Lavender Top Tube (LTT) ​ACD Yellow Top Tube (YTT) ​4 mL 2 mL
Collection Processing

Refrigerate specimens must arrive within 5 days (120 hours) of collection, and ambient specimens must arrive within 3 days (72 hours) of collection. Collect and package specimen as close to shipping time as possible.

Necessary Information:

The following information is required:

1. Pertinent clinical history including if the patient has a diagnosis of chronic myelogenous leukemia or other BCR/ABL1-positive neoplasm

2. Date of collection

3. Specimen source (blood or bone marrow)

Specimen Stability Information
Specimen Type Temperature Time
​Varies ​ ​Refrigerated (preferred) 5 days
​Ambient ​72 hours
Rejection Criteria
Gross hemolysis or moderately to severely clotted
Useful For
Monitoring response to therapy in patients with known e1/a2 BCR/ABL1 (p190) fusion forms.
Reference Range Information
Performing Location Reference Range
​Mayo Clinic Laboratories ​ ​ ​The presence or absence of the BCR/ABL1 mRNA fusion form producing the p190 fusion protein is reported. If positive, the level is reported as the ratio of BCR/ABL1 (p190) transcript to ABL1 transcript in the form of a percentage.
Interpretation
An interpretive report will be provided.
For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Report Available Methodology/Instrumentation
​Mayo Clinic Laboratories ​Monday through Saturday ​4 to 8 days ​Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​81207
For most current information refer to the Marshfield Laboratory online reference manual.